A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and
safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin
lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab
vedotin in combination with rituximab in patients with relapsed or refractory diffuse large
B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression
and response in DLBCL (Part C).